Monash University

Company

Related News

Monash University Partners with Ono Pharmaceutical for Autoimmune Disease Therapies

Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.

Related Clinical Trials

NCT ID Title Status Phase
NCT07600892

Pain-at-Work Toolkit (Definitive Trial)

NOT_YET_RECRUITING NA
NCT07481435

TRacheostomy in DElphi for iNTensive Care' (TRiDENT)

NOT_YET_RECRUITING
NCT07438262

The AminoECMO Pilot Trial

NOT_YET_RECRUITING PHASE2
NCT07428473

A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

NOT_YET_RECRUITING PHASE1
NCT07337382

The Optimising Isolation, Quarantine and Distancing Study for COVID-19

ACTIVE_NOT_RECRUITING
NCT07300254

Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women-only With Early Infectious Syphilis: Implications for Transmission

RECRUITING
NCT07254000

Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants

RECRUITING PHASE2
NCT07224347

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

ACTIVE_NOT_RECRUITING
NCT07202091

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

RECRUITING PHASE2/PHASE3
NCT07202078

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

RECRUITING PHASE2/PHASE3